GlassScriptPhysician profile
Caleb P Blackburn
NPI 1215433685
$1,373.55
in general payments reported to CMS, 2019-2025
13 companies · $395 in 2025
The $395 reported for 2025 was more than what a typical Oral & Maxillofacial Surgery provider received nationally (typical 2025 total: $184).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $156 · 2022: $180 · 2023: $185 · 2024: $458 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,038.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axogen | $287.90 | 2021-2024 | Avance Nerve Graft, Axoguard Nerve Cap, Axoguard Nerve Protector |
| Stryker Corporation | $198.87 | 2024-2025 | Vsp System, Vsp Cranial |
| Medical Device Business Services, INC. | $180.00 | 2022 | |
| Baxter Healthcare | $149.95 | 2025 | Floseal |
| Sanara Medtech INC. | $144.78 | 2024 | Celleraterx |
| Acera Surgical, INC. | $142.72 | 2025 | Restrata Wound Matrix |
| Janssen Pharmaceuticals, INC | $64.79 | 2023 | Xarelto |
| Kerecis Limited | $61.12 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Merck Sharp & Dohme LLC | $57.83 | 2023-2025 | Keytruda |
| Zimvie INC. | $32.20 | 2024 | |
| Novartis Pharmaceuticals Corporation | $25.08 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.23 | 2023 | Ninlaro |
| Straumann USA LLC | $14.08 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Blackburn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.